Reported Early July 17, Halozyme Therapeutics, Inc. Reports Topline Data From Argenx's ADHERE Study Of VYVGART Hytrulo With Halozyme's ENHANZE Drug Delivery Technology In Patients With Chronic Inflammatory Demyelinating Polyneuropathy
Portfolio Pulse from Happy Mohamed
Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced positive topline data from the ADHERE study evaluating VYVGART® Hytrulo with ENHANZE® in adults with chronic inflammatory demyelinating polyneuropathy (CIDP). The study met its primary endpoint demonstrating a significantly lower risk of relapse with VYVGART® Hytrulo compared to placebo. This is the second successful outcome for VYVGART Hytrulo this year, with two additional study readouts expected in the fourth quarter.
July 17, 2023 | 4:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Halozyme's positive topline data from the ADHERE study could potentially boost the company's stock in the short term as it indicates progress in their drug development.
Positive clinical trial results often lead to increased investor confidence, potentially driving up the stock price. The successful outcome of the ADHERE study indicates progress in Halozyme's drug development, which could attract more investors to the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100